Format

Send to

Choose Destination
Cancer Treat Rev. 2013 Feb;39(1):18-26. doi: 10.1016/j.ctrv.2012.03.006. Epub 2012 Apr 24.

Targeted radio-nuclide therapy of skeletal metastases.

Author information

1
Dept. of Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA. osartor@tulane.edu

Abstract

In this review, we will focus on one particular class of stromal targeted therapy, i.e. the bone seeking radiopharmaceuticals (BSRs), but will also highlight selected issues related to the bone stroma as these concepts are new, rapidly evolving, and clearly linked to the underlying BSR mechanisms of targeting and action. Herein we review clinical BSR-trials of significance with randomized trials at center stage. Furthermore, we cover a new class of BSR in late clinical development based on bone-stromal targeted alpha-particle irradiation. Lastly, we discuss potential advances in combining BSR with bisphosphonates and/or chemotherapy and emphasize the feasibility of repeated dosing.

PMID:
22534284
DOI:
10.1016/j.ctrv.2012.03.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science Icon for Norwegian BIBSYS system
Loading ...
Support Center